Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arcus Biosciences Inc 3928 Point Eden Way Hayward CA 94545 USA

www.arcusbio.com Employees: 627 P: 510-694-6200

Sector:

Medical

Description:

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.

Key Statistics

Overview:

Market Capitalization, $K 2,324,680
Enterprise Value, $K 2,222,680
Shares Outstanding, K 107,974
Annual Sales, $ 258,000 K
Annual Net Income, $ -283,000 K
Last Quarter Sales, $ 26,000 K
Last Quarter Net Income, $ -135,000 K
EBIT, $ -375,000 K
EBITDA, $ -390,000 K
60-Month Beta 0.75
% of Insider Shareholders 9.60%
% of Institutional Shareholders 92.89%
Float, K 97,608
% Float 90.40%
Short Volume Ratio 0.32

Growth:

1-Year Return 25.47%
3-Year Return -30.30%
5-Year Return -33.07%
5-Year Revenue Growth 1,620.00%
5-Year Earnings Growth -62.69%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.27 on 10/28/25
Next Earnings Date 02/24/26
Earnings Per Share ttm -3.44
EPS Growth vs. Prev Year -27.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

RCUS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -68.17%
Return-on-Assets % -31.32%
Profit Margin % -109.69%
Debt/Equity 0.22
Price/Sales 10.52
Price/Cash Flow N/A
Price/Book 6.23
Book Value/Share 4.04
Interest Coverage -69.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar